Use of Topical Small Molecule Technology to Improve Patient Outcomes in the Diabetic Wound Care Setting

Patients were chosen at random by primary investigator based upon initial presentation with dry, cracked, and/or reddened skin, with underlying complications from compromised microvasculature. Intervention was conducted by using topical products designed to utilize small molecule technologies, with a molecular weight of fewer than 500 Da, to deliver, via topical diffusion, nutrients and antioxidants through the skin layers to address issues stemming from inadequate blood flow to the dermis. An "all-in-one" moisturizing cleansing lotion was applied to the affected areas and washed gently with a warm damp cloth. After cleansing, the skin was treated with a moisturizing skin cream or a chlorhexidine-containing skin shield on areas with redness or advanced breakdown. All products contain dimethicone as an active ingredient and are classified as OTC skin protectants per approved FDA monographs. Patients were evaluated by the primary investigator for noticeable resolution or improvements in dryness, scaling, skin cracks, and erythema.